Adam K. Noah

Dr. Noah provides coverage of the biotechnology and medical device industries.
He has been an active member of the scientific and financial communities for over 10 years.
Most recently, he worked in the intellectual property department of Diversa Corporation in San Diego.
Previously, he was at Roth Capital Partners in Los Angeles where the healthcare research group provided coverage of companies such as AMGN, AMLN, IDBE, ISIS, and NABI.
He has been published as both a scientist and a management consultant.
Dr. Noah was a post-doctoral fellow at the Salk Institute for Biological Studies, where he studied viral-induced oncogenesis of immune cells.
He received his MBA from San Diego State University while completing his doctoral dissertation in cell signaling at the University of California San Diego School of Medicine.
Dr. Noah holds the Series 7, 63, 86, and 87 registrations.